Company
Paragonix Technologies
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
7
510(k), De Novo and PMA
Device trials
4
As lead sponsor, any status
Adverse event reports
9
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$23.7M
1 Form D offering, 2023 to 2023
Equity
$23.7M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $23.7M raised of $23.7M sought, first sale Mar 3, 2023, 11 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Mar 3, 2023 | Equity | $23.7M | $23.7M | 11 | Rule 506(b) | Form D ↗Mar 14, 2023 |
Company details
From the company's latest Form D.
- Legal name
- Paragonix Technologies, Inc.
- Headquarters
- Cambridge, Massachusetts
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Technology
- SEC filer
- CIK 1969117 ↗
Executives, directors and promoters
As listed on the latest Form D.
6 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
The investor database is free with an account
Sign up free with your name, company and ZIP code to see the 5%+ shareholders and government grant funders behind device companies.
Latest FDA decisions
K254305 · Decided Jan 30, 2026 · 30 days after receipt
Device type: System, Perfusion, Kidney (KDN) · GI, Urology & Nephrology
6 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Global Utilization And Registry Database for Improved heArt preservatioNEnrolling by invitation
NCT04141605 · 4,000 participants (planned) · Start Feb 14, 2020 · Primary completion Dec 31, 2028
Device: SherpaPak Cardiac Transport System · For: Heart Diseases; Heart Failure; Heart Defects, Congenital
Sites: Stanford, California; Washington D.C., District of Columbia; Gainesville, Florida · 22 sites in all
3 more trials with a free account
Reports received
9
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
9
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 1 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 2 | 0 | 0 | 0 |
| Apr 26 | 1 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 6 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
The full in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Paragonix Technologies Inc. KidneyVault Portable Renal Perfusion System REF# PRGNX-8008-001Open, Classified
Z-2967-2026 · Started Jul 20, 2026 · Posted by FDA Aug 14, 2026
Reason given: Due to a firmware defect, the portable organ transfer device datalogger may lose its configuration, resulting in a blank screen and loss of displayed preservation parameters.
Cause as FDA categorized it: Software design · Device type: System, Perfusion, Kidney (KDN)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.